Next Science Limited announced that BlastX antimicrobial wound gel has been cleared by the Therapeutic Goods Administration. This TGA clearance allows Next Science to sell BlastX in Australia for use as a hydrogel wound dressing on all open wounds. The product has shown excellent efficacy on non-healing wounds such as diabetic foot ulcers, pressure sores, venous leg ulcers and non-healing surgical wounds for example for patients who have undergone a caesarian section operation. First sales in Australia are expected to commence in June 2021 directly from Next Science. BlastX is an antimicrobial wound gel based on Next Science's patented, non-toxic, biofilm-disrupting Xbio technology. BlastX deconstructs the bacterial biofilm; the gel envelops and eliminates the bacteria and then defends from recolonisation while maintaining a moist wound environment conducive to healing. The product is ideal for the treatment of non-healing wounds such as diabetic foot ulcers, bed sores (pressure ulcers) and venous leg ulcers as well as preventing infections in acute wounds from trauma and surgical incision sites. BlastX can be used in hospital, pre-hospital and clinic environments as well as home care.